Meta has an AI for brain typing, but it’s stuck in the lab

Back in 2017, Facebook unveiled plans for a brain-reading hat that you could use to text just by thinking. “We’re working on a system that will let you type straight from your brain,” CEO Mark Zuckerberg shared in a post that year.

Now the company, since renamed Meta, has actually done it. Except it weighs a half a ton, costs $2 million, and won’t ever leave the lab.

Still, it’s pretty cool that neuroscience and AI researchers working for Meta have managed to analyze people’s brains as they type and determine what keys they are pressing, just from their thoughts.

The research, described in two papers posted by the company (here and here), as well as a blog post, is particularly impressive because the thoughts of the subjects were measured from outside their skulls using a magnetic scanner, and then processed using a deep neural network.

“As we’ve seen time and again, deep neural networks can uncover remarkable insights when paired with robust data,” says Sumner Norman, founder of Forest Neurotech, who wasn’t involved in the research but credits Meta with going “to great lengths to collect high-quality data.”

According to Jean-Rémi King, leader of Meta’s “Brain & AI” research team, the system is able to determine what letter a skilled typist has pressed as much as 80% of the time, an accuracy high enough to reconstruct full sentences from the brain signals.

Facebook’s original quest for a consumer brain-reading cap or headband ran into technical obstacles, and after four years, the company scrapped the idea.

But Meta never stopped supporting basic research on neuroscience, something it now sees as an important pathway to more powerful AIs that learn and reason like humans. King says his group, based in Paris, is specifically tasked with figuring out “the principles of intelligence” from the human brain.

“Trying to understand the precise architecture or principles of the human brain could be a way to inform the development of machine intelligence,” says King. “That’s the path.”

The typing system is definitely not a commercial product, nor is it on the way to becoming one. The magnetoencephalography scanner used in the new research collects magnetic signals produced in the cortex as brain neurons fire. But it is large and expensive and needs to be operated in a shielded room, since Earth’s magnetic field is a trillion times stronger than the one in your brain. 

Norman likens the device to “an MRI machine tipped on its side and suspended above the user’s head.”

What’s more, says King, the second a subject’s head moves, the signal is lost. “Our effort is not at all toward products,” he says. “In fact, my message is always to say I don’t think there is a path for products because it’s too difficult.”

The typing project was carried out with 35 volunteers at a research site in Spain, the Basque Center on Cognition, Brain, and Language. Each spent around 20 hours inside the scanner typing phrases like “el procesador ejecuta la instrucción” (the processor executes the instruction) while their brain signals were fed into a deep-learning system that Meta is calling Brain2Qwerty, in a reference to the layout of letters on a keyboard.

The job of that deep-learning system is to figure out which brain signals mean someone is typing an a, which mean z, and so on. Eventually, after it sees an individual volunteer type several thousand characters, the model can guess what key people were actually pressing on. 

In the first preprint, Meta researchers report that the average error rate was about 32%—or nearly one out of three letters wrong. Still, according to Meta, its results are most accurate yet for brain typing using a full alphabet keyboard and signals collected outside the skull.

Research on brain reading has been advancing quickly, although the most effective approaches use electrodes implanted into the brain, or directly on its surface. These are known as “invasive” brain computer interfaces. Although they require brain surgery, they can very accurately gather electrical information from small groups of neurons.

In 2023, for instance, a person who lost her voice from ALS was able to speak via brain-reading software connected to a voice synthesizer. Neuralink, founded by Elon Musk, is testing its own brain implant that gives paralyzed people control over a cursor.

Meta says its own efforts remain oriented toward basic research into the nature of intelligence.

And that is where the big magnetic scanner can help. Even though it isn’t practical for patients and doesn’t measure individual neurons, it is able to look at the whole brain, broadly, and all at once. 

The Meta scientists say that in a second research effort, using the same typing data, they used this broader view to amass evidence that the brain produces language information in a top-down fashion, with an initial signal for a sentence kicking off separate signals for words, syllables, and finally typed letters.

“The core claim is that the brain structures language production hierarchically,” says Norman. That’s not a new idea, but Meta’s report highlights “how these different levels interact as a system,” says Norman.

Those types of insights could eventually shape the design of artificial-intelligence systems. Some of these, like chatbots, already rely extensively on language in order to process information and reason, just as people do.

“Language has become a foundation of AI,” King says. “So the computational principles that allow the brain, or any system, to acquire such ability is the key motivation behind this work.”

Correction: Meta posted two papers describing its brain-typing results on its website. An earlier version of this story incorrectly said they had been published at arXiv.org.

How the tiny microbes in your mouth could be putting your health at risk

This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.

This week I’ve been working on a piece about teeth. Well, sort of teeth. Specifically, lab-grown bioengineered teeth. Researchers have created these teeth with a mixture of human and pig tooth cells and grown them in the jaws of living mini pigs.

“We’re working on trying to create functional replacement teeth,” Pamela Yelick of Tufts University, one of the researchers behind the work, told me. The idea is to develop an alternative to titanium dental implants. Replacing lost or damaged teeth with healthy, living, lab-grown ones might be a more appealing option than drilling a piece of metal into a person’s jawbone.

Current dental implants can work well, but they’re not perfect. They don’t attach to bones and gums in the same way that real teeth do. And around 20% of people who get implants end up developing an infection called peri-implantitis, which can lead to bone loss.

It is all down to the microbes that grow on them. There’s a complex community of microbes living in our mouths, and disruptions can lead to infection. But these organisms don’t just affect our mouths; they also seem to be linked to a growing number of disorders that can affect our bodies and brains. If you’re curious, read on.

The oral microbiome, as it is now called, was first discovered in 1670 by Antonie van Leeuwenhoek, a self-taught Dutch microbiologist. “I didn’t clean my teeth for three days and then took the material that had lodged in small amounts on the gums above my front teeth … I found a few living animalcules,” he wrote in a letter to the Royal Society at the time.

Van Leeuwenhoek had used his own homemade microscopes to study the “animalcules” he found in his mouth. Today, we know that these organisms include bacteria, archaea, fungi, and viruses, each of which comes in lots of types. “Everyone’s mouth is home to hundreds of bacterial species,” says Kathryn Kauffman at the University of Buffalo, who studies the oral microbiome.

These organisms interact with each other and with our own immune systems, and researchers are still getting to grips with how the interactions work. Some microbes feed on sugars or fats in our diets, for example, while others seem to feed on our own cells. Depending on what they consume and produce, microbes can alter the environment of the mouth to either promote or inhibit the growth of other microbes.

This complex microbial dance seems to have a really important role in our health. Oral diseases and even oral cancers have been linked to an imbalance in the oral microbiome, which scientists call “dysbiosis.” Tooth decay, for example, has been attributed to an overgrowth of microbes that produce acids that can damage teeth. 

Specific oral microbes are also being linked to an ever-growing list of diseases of the body and brain, including rheumatoid arthritis, metabolic disease, cardiovascular diseases, inflammatory bowel disease, colorectal cancer, and more.

There’s also growing evidence that these oral microbes contribute to neurodegenerative disease. A bacterium called P. gingivalis, which plays a role in the development of chronic periodontitis, has been found in the brains of people with Alzheimer’s disease. And people who are infected with P. gingivalis also experience a decline in their cognitive abilities over a six-month period.

Scientists are still figuring out how oral microbes might travel from the mouth to cause disease elsewhere. In some cases, “you swallow the saliva that contains them … and they can lodge in your heart and other parts of the body,” says Yelick. “They can result in a systemic inflammation that just happens in the background.”

In other cases, the microbes may be hitching a ride in our own immune cells to journey through the bloodstream, as the “Trojan horse hypothesis” posits. There’s some evidence that Fusobacterium nucleatum, a bacterium commonly found in the mouth, does this by hiding in white blood cells. 

There’s a lot to learn about exactly how these tiny microbes are exerting such huge influence over everything from our metabolism and bone health to our neurological function. But in the meantime, the emerging evidence is a good reminder to us all to look after our teeth. At least until lab-grown ones become available.


Now read the rest of The Checkup

Read more from MIT Technology Review‘s archive

You can read more about Yelick’s attempt to grow humanlike teeth in mini pigs here.

The gut microbiome is even more complex than the one in our mouths. Some scientists believe that people in traditional societies have the healthiest collections of gut microbes. But research on the topic has left some of the people in those groups feeling exploited

Research suggests our microbiomes change as we age. Scientists are exploring whether maintaining our microbiomes might help us stave off age-related disease.

The makeup of a gut microbiome can be assessed by analyzing fecal samples. This research might be able to reveal what a person has eaten and help provide personalized dietary advice.

There are also communities of microbes living on our skin. Scientists have engineered skin microbes to prevent and treat cancer in mice. Human trials are in the works.

From around the web

Argentina has declared that it will withdraw from the World Health Organization, following a similar move from the US. President Javier Milei has criticized the WHO for its handling of the covid-19 pandemic and called it a “nefarious organization.” (Al Jazeera)

Dairy cows in Nevada have been infected with a form of bird flu different from the one that has been circulating in US dairy herds for months. (The New York Times)

Staff at the US Centers for Disease Control and Prevention have been instructed to withdraw pending journal publications that mention terms including “transgender” and “pregnant people.” But the editors of the British Medical Journal have said they “will not retract published articles on request by an author on the basis that they contained so-called banned words.” “Retraction occurs in circumstances where clear evidence exists of major errors, data fabrication, or falsification that compromise the reliability of the research findings. It is not a matter of author request,” two editors have written. (BMJ)

Al Nowatzki had been chatting to his AI girlfriend, Erin, for months. Then, in late January, Erin told him to kill himself, and provided explicit instructions on how to do so. (MIT Technology Review)

Is our use of the internet and AI tools making us cognitively lazy? “Digital amnesia” might just be a sign of an aging brain. (Nature)

How measuring vaccine hesitancy could help health professionals tackle it

This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.

This week, Robert F. Kennedy Jr., President Donald Trump’s pick to lead the US’s health agencies, has been facing questions from senators as part of his confirmation hearing for the role. So far, it’s been a dramatic watch, with plenty of fiery exchanges, screams from audience members, and damaging revelations.

There’s also been a lot of discussion about vaccines. Kennedy has long been a vocal critic of vaccines. He has spread misinformation about the effects of vaccines. He’s petitioned the government to revoke the approval of vaccines. He’s sued pharmaceutical companies that make vaccines

Kennedy has his supporters. But not everyone who opts not to vaccinate shares his worldview. There are lots of reasons why people don’t vaccinate themselves or their children.

Understanding those reasons will help us tackle an issue considered to be a huge global health problem today. And plenty of researchers are working on tools to do just that.

Jonathan Kantor is one of them. Kantor, who is jointly affiliated with the University of Pennsylvania in Philadelphia and the University of Oxford in the UK, has been developing a scale to measure and assess “vaccine hesitancy.”

That term is what best captures the diverse thoughts and opinions held by people who don’t get vaccinated, says Kantor. “We used to tend more toward [calling] someone … a vaccine refuser or denier,” he says. But while some people under this umbrella will be stridently opposed to vaccines for various reasons, not all of them will be. Some may be unsure or ambivalent. Some might have specific fears, perhaps about side effects or even about needle injections.

Vaccine hesitancy is shared by “a very heterogeneous group,” says Kantor. That group includes “everyone from those who have a little bit of wariness … and want a little bit more information … to those who are strongly opposed and feel that it is their mission in life to spread the gospel regarding the risks of vaccination.”

To begin understanding where individuals sit on this spectrum and why, Kantor and his colleagues scoured published research on vaccine hesitancy. They sent surveys to 50 people, asking them detailed questions about their feelings on vaccines. The researchers were looking for themes: Which issues kept cropping up?

They found that prominent concerns about vaccines tend to fall into three categories: beliefs, pain, and deliberation. Beliefs might be along the lines of “It is unhealthy for children to be vaccinated as much as they are today.” Concerns around pain center more on the immediate consequences of the vaccination, such as fears about the injection. And deliberation refers to the need some people feel to “do their own research.”

Kantor and his colleagues used their findings to develop a 13-question survey, which they trialed in 500 people from the UK and 500 more from the US. They found that responses to the questionnaire could predict whether someone had been vaccinated against covid-19.

Theirs is not the first vaccine hesitancy scale out there—similar questionnaires have been developed by others, often focusing on parents’ feelings about their children’s vaccinations. But Kantor says this is the first to incorporate the theme of deliberation—a concept that seems to have become more popular during the early days of covid-19 vaccination rollouts.

Nicole Vike at the University of Cincinnati and her colleagues are taking a different approach. They say research has suggested that how people feel about risks and rewards seems to influence whether they get vaccinated (although not necessarily in a simple or direct manner).

Vike’s team surveyed over 4,000 people to better understand this link, asking them information about themselves and how they felt about a series of pictures of sports, nature scenes, cute and aggressive animals, and so on. Using machine learning, they built a model that could predict, from these results, whether a person would be likely to get vaccinated against covid-19.

This survey could be easily distributed to thousands of people and is subtle enough that people taking it might not realize it is gathering information about their vaccine choices, Vike and her colleagues wrote in a paper describing their research. And the information collected could help public health centers understand where there is demand for vaccines, and conversely, where outbreaks of vaccine-preventable diseases might be more likely.

Models like these could be helpful in combating vaccine hesitancy, says Ashlesha Kaushik, vice president of the Iowa Chapter of the American Academy of Pediatrics. The information could enable health agencies to deliver tailored information and support to specific communities that share similar concerns, she says.

Kantor, who is a practicing physician, hopes his questionnaire could offer doctors and other health professionals insight into their patients’ concerns and suggest ways to address them. It isn’t always practical for doctors to sit down with their patients for lengthy, in-depth discussions about the merits and shortfalls of vaccines. But if a patient can spend a few minutes filling out a questionnaire before the appointment, the doctor will have a starting point for steering a respectful and fruitful conversation about the subject.

When it comes to vaccine hesitancy, we need all the insight we can get. Vaccines prevent millions of deaths every year. One and half million children under the age of five die every year from vaccine-preventable diseases, according to the children’s charity UNICEF. In 2019, the World Health Organization included “vaccine hesitancy” on its list of 10 threats to global health.

When vaccination rates drop, we start to see outbreaks of the diseases the vaccines protect against. We’ve seen this a lot recently with measles, which is incredibly infectious. Sixteen measles outbreaks were reported in the US in 2024.

Globally, over 22 million children missed their first dose of the measles vaccine in 2023, and measles cases rose by 20%. Over 107,000 people around the world died from measles that year, according to the US Centers for Disease Control and Prevention. Most of them were children.

Vaccine hesitancy is dangerous. “It’s really creating a threatening environment for these vaccine-preventable diseases to make a comeback,” says Kaushik. 

Kantor agrees: “Anything we can do to help mitigate that, I think, is great.”


Now read the rest of The Checkup

Read more from MIT Technology Review‘s archive

In 2021, my former colleague Tanya Basu wrote a guide to having discussions about vaccines with people who are hesitant. Kindness and nonjudgmentalism will get you far, she wrote.

In December 2020, as covid-19 ran rampant around the world, doctors took to social media platforms like TikTok to allay fears around the vaccine. Sharing their personal experiences was important—but not without risk, A.W. Ohlheiser reported at the time.

Robert F. Kennedy Jr. is currently in the spotlight for his views on vaccines. But he has also spread harmful misinformation about HIV and AIDS, as Anna Merlan reported.

mRNA vaccines have played a vital role in the covid-19 pandemic, and in 2023, the researchers who pioneered the science behind them were awarded a Nobel Prize. Here’s what’s next for mRNA vaccines.

Vaccines are estimated to have averted 154 million deaths in the last 50 years. That number includes 146 million children under the age of five. That’s partly why childhood vaccines are a public health success story.

From around the web

As Robert F. Kennedy Jr.’s Senate hearing continued this week, so did the revelations of his misguided beliefs about health and vaccines. Kennedy, who has called himself “an expert on vaccines,” said in 2021 that “we should not be giving Black people the same vaccine schedule that’s given to whites, because their immune system is better than ours”—a claim that is not supported by evidence. (The Washington Post)

And in past email exchanges with his niece, a primary-care physician at NYC Health + Hospitals in New York City, RFK Jr. made repeated false claims about covid-19 vaccinations and questioned the value of annual flu vaccinations. (STAT)

Towana Looney, who became the third person to receive a gene-edited pig kidney in December, is still healthy and full of energy two months later. The milestone makes Looney the longest-living recipient of a pig organ transplant. “I’m superwoman,” she told the Associated Press. (AP)

The Trump administration’s attempt to freeze trillions of dollars in federal grants, loans, and other financial assistance programs was chaotic. Even a pause in funding for global health programs can be considered a destruction, writes Atul Gawande. (The New Yorker)

How ultraprocessed is the food in your diet? This chart can help rank food items—but won’t tell you all you need to know about how healthy they are. (Scientific American)

Mice with two dads have been created using CRISPR

Mice with two fathers have been born—and have survived to adulthood—following a complex set of experiments by a team in China. 

Zhi-Kun Li at the Chinese Academy of Sciences in Beijing and his colleagues used CRISPR to create the mice, using a novel approach to target genes that normally need to be inherited from both male and female parents. They hope to use the same approach to create primates with two dads. 

Humans are off limits for now, but the work does help us better understand a strange biological phenomenon known as imprinting, which causes certain genes to be expressed differently depending on which parent they came from. For these genes, animals inherit part of a “dose” from each parent, and the two must work in harmony to create a healthy embryo. Without both doses, gene expression can go awry, and the resulting embryos can end up with abnormalities.

This is what researchers have found in previous attempts to create mice with two dads. In the 1980s, scientists in the UK tried injecting the DNA-containing nucleus of a sperm cell into a fertilized egg cell. The resulting embryos had DNA from two males (as well as a small amount of DNA from a female, in the cytoplasm of the egg).

But when these embryos were transferred to the uteruses of surrogate mouse mothers, none of them resulted in a healthy birth, seemingly because imprinted genes from both paternal and maternal genomes are needed for development. 

Li and his colleagues took a different approach. The team used gene editing to knock out imprinted genes altogether.

Around 200 of a mouse’s genes are imprinted, but Li’s team focused on 20 that are known to be important for the development of the embryo.

In an attempt to create healthy mice with DNA from two male “dads,” the team undertook a complicated set of experiments. To start, the team cultured cells with sperm DNA to collect stem cells in the lab. Then they used CRISPR to disrupt the 20 imprinted genes they were targeting.

These gene-edited cells were then injected, along with other sperm cells, into egg cells that had had their own nuclei removed. The result was embryonic cells with DNA from two male mice. These cells were then injected into a type of “embryo shell” used in research, which provides the cells required to make a placenta. The resulting embryos were transferred to the uteruses of female mice.

It worked—to some degree. Some of the embryos developed into live pups, and they even survived to adulthood. The findings were published in the journal Cell Stem Cell.

“It’s exciting,” says Kotaro Sasaki, a developmental biologist at the University of Pennsylvania, who was not involved in the work. Not only have Li and his team been able to avoid a set of imprinting defects, but their approach is the second way scientists have found to create mice using DNA from two males.

The finding builds on research by Katsuhiko Hayashi, now at Osaka University in Japan, and his colleagues. A couple of years ago, that team presented evidence that they had found a way to take cells from the tails of adult male mice and turn them into immature egg cells. These could be fertilized with sperm to create bi-paternal embryos. The mice born from those embryos can reach adulthood and have their own offspring, Hayashi has said.

Li’s team’s more complicated approach was less successful. Only a small fraction of the mice survived, for a start. The team transferred 164 gene-edited embryos, but only seven live pups were born. And those that were born weren’t entirely normal, either. They grew to be bigger than untreated mice, and their organs appeared enlarged. They didn’t live as long as normal mice, and they were infertile.

It would be unethical to do such risky research with human cells and embryos. “Editing 20 imprinted genes in humans would not be acceptable, and producing individuals who could not be healthy or viable is simply not an option,” says Li.

“There are numerous issues,” says Sasaki. For a start, a lot of the technical lab procedures the team used have not been established for human cells. But even if we had those, this approach would be dangerous—knocking out human genes could have untold health consequences. 

“There’s lots and lots of hurdles,” he says. “Human applications [are] still quite far.”

Despite that, the work might shed a little more light on the mysterious phenomenon of imprinting. Previous research has shown that mice with two moms appear smaller, and live longer than expected, while the current study shows that mice with two dads are overgrown and die more quickly. Perhaps paternal imprinted genes support growth and maternal ones limit it, and animals need both to reach a healthy size, says Sasaki.

The US withdrawal from the WHO will hurt us all

This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.

On January 20, his first day in office, US president Donald Trump signed an executive order to withdraw the US from the World Health Organization. “Ooh, that’s a big one,” he said as he was handed the document.

The US is the biggest donor to the WHO, and the loss of this income is likely to have a significant impact on the organization, which develops international health guidelines, investigates disease outbreaks, and acts as an information-sharing hub for member states.

But the US will also lose out. “It’s a very tragic and sad event that could only hurt the United States in the long run,” says William Moss, an epidemiologist at Johns Hopkins Bloomberg School of Public Health in Baltimore.

Trump appears to take issue with the amount the US donates to the WHO. He points out that it makes a much bigger contribution than China, a country with a population four times that of the US. “It seems a little unfair to me,” he said as he prepared to sign the executive order.

It is true that the US is far and away the biggest financial supporter of the WHO. The US contributed $1.28 billion over the two-year period covering 2022 and 2023. By comparison, the second-largest donor, Germany, contributed $856 million in the same period. The US currently contributes 14.5% of the WHO’s total budget.

But it’s not as though the WHO sends a billion-dollar bill to the US. All member states are required to pay membership dues, which are calculated as a percentage of a country’s gross domestic product. For the US, this figure comes to $130 million. China pays $87.6 million. But the vast majority of the US’s contributions to the WHO are made on a voluntary basis—in recent years, the donations have been part of multibillion-dollar spending on global health by the US government. (Separately, the Bill and Melinda Gates Foundation contributed $830 million over 2022 and 2023.)

There’s a possibility that other member nations will increase their donations to help cover the shortfall left by the US’s withdrawal. But it is not clear who will step up—or what implications it will have to change the structure of donations.

Martin McKee, a professor of European public health at the London School of Hygiene and Tropical Medicine, thinks it is unlikely that European members will increase their contributions by much. China, India, Brazil, South Africa, and the Gulf states, on the other hand, may be more likely to pay more. But again, it isn’t clear how this will pan out, or whether any of these countries will expect greater influence over global health policy decisions as a result of increasing their donations.

WHO funds are spent on a range of global health projects—programs to eradicate polio, rapidly respond to health emergencies, improve access to vaccines and medicines, develop pandemic prevention strategies, and more. The loss of US funding is likely to have a significant impact on at least some of these programs.

“Diseases don’t stick to national boundaries, hence this decision is not only concerning for the US, but in fact for every country in the world,” says Pauline Scheelbeek at the London School of Hygiene and Tropical Medicine.“With the US no longer reporting to the WHO nor funding part of this process, the evidence on which public health interventions and solutions should be based is incomplete.”

“It’s going to hurt global health,” adds Moss. “It’s going to come back to bite us.”

There’s more on how the withdrawal could affect health programs, vaccine coverage, and pandemic preparedness in this week’s coverage.


Now read the rest of The Checkup

Read more from MIT Technology Review‘s archive

This isn’t the first time Donald Trump has signaled his desire for the US to leave the WHO. He proposed a withdrawal during his last term, in 2020. While the WHO is not perfect, it needs more power and funding, not less, Charles Kenny, director of technology and development at the Center for Global Development, argued at the time.

The move drew condemnation from those working in public health then, too. The editor in chief of the medical journal The Lancet called it “a crime against humanity,” as Charlotte Jee reported.

In 1974, the WHO launched an ambitious program to get lifesaving vaccines to all children around the world. Fifty years on, vaccines are thought to have averted 154 million deaths—including 146 million in children under the age of five. 

The WHO has also seen huge success in its efforts to eradicate polio. Today, wild forms of the virus have been eradicated in all but two countries. But vaccine-derived forms of the virus can still crop up around the world.

At the end of a round of discussions in September among WHO member states working on a pandemic agreement, director-general Tedros Adhanom Ghebreyesus remarked, “The next pandemic will not wait for us, whether from a flu virus like H5N1, another coronavirus, or another family of viruses we don’t yet know about.” The H5N1 virus has been circulating on US dairy farms for months now, and the US is preparing for potential human outbreaks.

From around the web

People with cancer paid $45,000 for an experimental blood-filtering treatment, delivered at a clinic in Antigua, after being misled about its effectiveness. Six of them have died since their treatments. (The New York Times)

The Trump administration has instructed federal health agencies to pause all external communications, such as health advisories, weekly scientific reports, updates to websites, and social media posts. (The Washington Post)

A new “virtual retina,” modeled on human retinas, has been developed to study the impact of retinal implants. The three-dimensional model simulates over 10,000 neurons. (Brain Stimulation)

Trump has signed an executive order stating that “it is the policy of the United States to recognize two sexes, male and female.” The document “defies decades of research into how human bodies grow and develop,” STAT reports, and represents “a dramatic failure to understand biology,” according to a neuroscientist who studies the development of sex. (STAT)

Attention, summer holiday planners: Biting sandflies in the Mediterranean region are transmitting Toscana virus at an increasing rate. The virus is a major cause of central nervous system disorders in the region. Italy saw a 2.6-fold increase in the number of reported infections between the 2016–21 period and 2022–23. (Eurosurveillance)

This is what might happen if the US withdraws from the WHO

On January 20, his first day in office, US president Donald Trump signed an executive order to withdraw the US from the World Health Organization. “Ooh, that’s a big one,” he said as he was handed the document.

The US is the biggest donor to the WHO, and the loss of this income is likely to have a significant impact on the organization, which develops international health guidelines, investigates disease outbreaks, and acts as an information-sharing hub for member states.

But the US will also lose out. “It’s a very tragic and sad event that could only hurt the United States in the long run,” says William Moss, an epidemiologist at Johns Hopkins Bloomberg School of Public Health in Baltimore.

A little unfair?

Trump appears to take issue with the amount the US donates to the WHO. He points out that it makes a much bigger contribution than China, a country with a population four times that of the US. “It seems a little unfair to me,” he said as he prepared to sign the executive order.

It is true that the US is far and away the biggest financial supporter of the WHO. The US contributed $1.28 billion over the two-year period covering 2022 and 2023. By comparison, the second-largest donor, Germany, contributed $856 million in the same period. The US currently contributes 14.5% of the WHO’s total budget.

But it’s not as though the WHO sends a billion-dollar bill to the US. All member states are required to pay membership dues, which are calculated as a percentage of a country’s gross domestic product. For the US, this figure comes to $130 million. China pays $87.6 million. But the vast majority of the US’s contributions to the WHO are made on a voluntary basis—in recent years, the donations have been part of multibillion-dollar spending on global health by the US government. (Separately, the Bill and Melinda Gates Foundation contributed $830 million over 2022 and 2023.)

There’s a possibility that other member nations will increase their donations to help cover the shortfall left by the US’s withdrawal. But it is not clear who will step up—or what implications changing the structure of donations will have.

Martin McKee, a professor of European public health at the London School of Hygiene and Tropical Medicine, thinks it is unlikely that European members will increase their contributions by much. The Gulf states, China, India, Brazil, and South Africa, on the other hand, may be more likely to pay more. But again, it isn’t clear how this will pan out, or whether any of these countries will expect greater influence over global health policy decisions as a result of increasing their donations.

Deep impacts

WHO funds are spent on a range of global health projects—programs to eradicate polio, rapidly respond to health emergencies, improve access to vaccines and medicines, develop pandemic prevention strategies, and more. The loss of US funding is likely to have a significant impact on at least some of these programs.

It is not clear which programs will lose funding, or when they will be affected. The US is required to give 12 months’ notice to withdraw its membership, but voluntary contributions might stop before that time is up. 

For the last few years, WHO member states have been negotiating a pandemic agreement designed to improve collaboration on preparing for future pandemics. The agreement is set to be finalized in 2025. But these discussions will be disrupted by the US withdrawal, says McKee. It will “create confusion about how effective any agreement will be and what it will look like,” he says.

The agreement itself won’t make as big an impact without the US as a signatory, either, says Moss, who is also a member of a WHO vaccine advisory committee. The US would not be held to information-sharing standards that other countries could benefit from, and it might not be privy to important health information from other member nations. The global community might also lose out on the US’s resources and expertise. “Having a major country like the United States not be a part of that really undermines the value of any pandemic agreement,” he says.

McKee thinks that the loss of funding will also affect efforts to eradicate polio, and to control outbreaks of mpox in the Democratic Republic of Congo, Uganda, and Burundi, which continue to report hundreds of cases per week. The virus “has the potential to spread, including to the US,” he points out.

“Diseases don’t stick to national boundaries, hence this decision is not only concerning for the US, but in fact for every country in the world,” says Pauline Scheelbeek at the London School of Hygiene and Tropical Medicine. “With the US no longer reporting to the WHO nor funding part of this process, the evidence on which public health interventions and solutions should be based is incomplete.”

Moss is concerned about the potential for outbreaks of vaccine-preventable diseases. Robert F. Kennedy Jr., Trump’s pick to lead the Department of Health and Human Services, is a prominent antivaccine advocate, and Moss worries about potential changes to vaccination-based health policies in the US. That, combined with a weakening of the WHO’s ability to control outbreaks, could be a “double whammy,” he says: “We’re setting ourselves up for large measles disease outbreaks in the United States.”

At the same time, the US is up against another growing threat to public health: the circulation of bird flu on poultry and dairy farms. The US has seen outbreaks of the H5N1 virus on poultry farms in all states, and the virus has been detected in 928 dairy herds across 16 states, according to the US Centers for Disease Control and Prevention. There have been 67 reported human cases in the US, and one person has died. While we don’t yet have evidence that the virus can spread between people, the US and other countries are already preparing for potential outbreaks.

But this preparation relies on a thorough and clear understanding of what is happening on the ground. The WHO provides an important role in information sharing—countries report early signs of outbreaks to the agency, which then shares the information with its members. This kind of information not only allows countries to develop strategies to limit the spread of disease but can also allow them to share genetic sequences of viruses and develop vaccines. Member nations need to know what’s happening in the US, and the US needs to know what’s happening globally. “Both of those channels of communication would be hindered by this,” says Moss.

As if all of that weren’t enough, the US also stands to suffer in terms of its reputation as a leader in global public health. “By saying to the world ‘We don’t care about your health,’ it sends a message that is likely to reflect badly on it,” says McKee. “It’s a classic lose-lose situation.”

“It’s going to hurt global health,” says Moss. “It’s going to come back to bite us.”

Update: this article was amended to include commentary from Pauline Scheelbeek.

What to expect from Neuralink in 2025

MIT Technology Review’s What’s Next series looks across industries, trends, and technologies to give you a first look at the future. You can read the rest of them here.

In November, a young man named Noland Arbaugh announced he’d be livestreaming from his home for three days straight. His broadcast was in some ways typical fare: a backyard tour, video games, meet mom.

The difference is that Arbaugh, who is paralyzed, has thin electrode-studded wires installed in his brain, which he used to move a computer mouse on a screen, click menus, and play chess. The implant, called N1, was installed last year by neurosurgeons working with Neuralink, Elon Musk’s brain-interface company.

The possibility of listening to neurons and using their signals to move a computer cursor was first demonstrated more than 20 years ago in a lab setting. Now, Arbaugh’s livestream is an indicator that Neuralink is a whole lot closer to creating a plug-and-play experience that can restore people’s daily ability to roam the web and play games, giving them what the company has called “digital freedom.”

But this is not yet a commercial product. The current studies are small-scale—they are true experiments, explorations of how the device works and how it can be improved. For instance, at some point last year, more than half the electrode-studded “threads” inserted into Aurbaugh’s brain retracted, and his control over the device worsened; Neuralink rushed to implement fixes so he could use his remaining electrodes to move the mouse.

Neuralink did not reply to emails seeking comment, but here is what our analysis of its public statements leads us to expect from the company in 2025.

More patients

How many people will get these implants? Elon Musk keeps predicting huge numbers. In August, he posted on X: “If all goes well, there will be hundreds of people with Neuralinks within a few years, maybe tens of thousands within five years, millions within 10 years.”

In reality, the actual pace is slower—a lot slower. That’s because in a study of a novel device, it’s typical for the first patients to be staged months apart, to allow time to monitor for problems. 

Neuralink has publicly announced that two people have received an implant: Arbaugh and a man referred to only as “Alex,” who received his in July or August. 

Then, on January 8, Musk disclosed during an online interview that there was now a third person with an implant. “We’ve got now three patients, three humans with Neuralinks implanted, and they are all working …well,” Musk said. During 2025, he added, “we expect to hopefully do, I don’t know, 20 or 30 patients.”  

Barring major setbacks, expect the pace of implants to increase—although perhaps not as fast as Musk says. In November, Neuralink updated its US trial listing to include space for five volunteers (up from three), and it also opened a trial in Canada with room for six. Considering these two studies only, Neuralink would carry out at least two more implants by the end of 2025 and eight by the end of 2026.

However, by opening further international studies, Neuralink could increase the pace of the experiments.

Better control

So how good is Arbaugh’s control over the mouse? You can get an idea by trying a game called Webgrid, where you try to click quickly on a moving target. The program translates your speed into a measure of information transfer: bits per second. 

Neuralink claims Arbaugh reached a rate of over nine bits per second, doubling the old brain-interface record. The median able-bodied user scores around 10 bits per second, according to Neuralink.

And yet during his livestream, Arbaugh complained that his mouse control wasn’t very good because his “model” was out of date. It was a reference to how his imagined physical movements get mapped to mouse movements. That mapping degrades over hours and days, and to recalibrate it, he has said, he spends as long as 45 minutes doing a set of retraining tasks on his monitor, such as imagining moving a dot from a center point to the edge of a circle.

Noland Arbaugh stops to calibrate during a livestream on X
@MODDEDQUAD VIA X

Improving the software that sits between Arbaugh’s brain and the mouse is a big area of focus for Neuralink—one where the company is still experimenting and making significant changes. Among the goals: cutting the recalibration time to a few minutes. “We want them to feel like they are in the F1 [Formula One] car, not the minivan,” Bliss Chapman, who leads the BCI software team, told the podcaster Lex Fridman last year.

Device changes

Before Neuralink ever seeks approval to sell its brain interface, it will have to lock in a final device design that can be tested in a “pivotal trial” involving perhaps 20 to 40 patients, to show it really works as intended. That type of study could itself take a year or two to carry out and hasn’t yet been announced.

In fact, Neuralink is still tweaking its implant in significant ways—for instance, by trying to increase the number of electrodes or extend the battery life. This month, Musk said the next human tests would be using an “upgraded Neuralink device.”

The company is also still developing the surgical robot, called R1, that’s used to implant the device. It functions like a sewing machine: A surgeon uses R1 to thread the electrode wires into people’s brains. According to Neuralink’s job listings, improving the R1 robot and making the implant process entirely automatic is a major goal of the company. That’s partly to meet Musk’s predictions of a future where millions of people have an implant, since there wouldn’t be enough neurosurgeons in the world to put them all in manually. 

“We want to get to the point where it’s one click,” Neuralink president Dongjin Seo told Fridman last year.

Robot arm

Late last year, Neuralink opened a companion study through which it says some of its existing implant volunteers will get to try using their brain activity to control not only a computer mouse but other types of external devices, including an “assistive robotic arm.”

We haven’t yet seen what Neuralink’s robotic arm looks like—whether it’s a tabletop research device or something that could be attached to a wheelchair and used at home to complete daily tasks.

But it’s clear such a device could be helpful. During Aurbaugh’s livestream he frequently asked other people to do simple things for him, like brush his hair or put on his hat.

Arbaugh demonstrates the use of Imagined Movement Control.
@MODDEDQUAD VIA X

And using brains to control robots is definitely possible—although so far only in a controlled research setting. In tests using a different brain implant, carried out at the University of Pittsburgh in 2012, a paralyzed woman named Jan Scheuermann was able to use a robot arm to stack blocks and plastic cups about as well as a person who’d had a severe stroke—impressive, since she couldn’t actually move her own limbs.

There are several practical obstacles to using a robot arm at home. One is developing a robot that’s safe and useful. Another, as noted by Wired, is that the calibration steps to maintain control over an arm that can make 3D movements and grasp objects could be onerous and time consuming.

Vision implant

In September, Neuralink said it had received “breakthrough device designation” from the FDA for a version of its implant that could be used to restore limited vision to blind people. The system, which it calls Blindsight, would work by sending electrical impulses directly into a volunteer’s visual cortex, producing spots of light called phosphenes. If there are enough spots, they can be organized into a simple, pixelated form of vision, as previously demonstrated by academic researchers.

The FDA designation is not the same as permission to start the vision study. Instead, it’s a promise by the agency to speed up review steps, including agreements around what a trial should look like. Right now, it’s impossible to guess when a Neuralink vision trial could start, but it won’t necessarily be this year. 

More money

Neuralink last raised money in 2023, collecting around $325 million from investors in a funding round that valued the company at over $3 billion, according to Pitchbook. Ryan Tanaka, who publishes a podcast about the company, Neura Pod, says he thinks Neuralink will raise more money this year and that the valuation of the private company could double.

Fighting regulators

Neuralink has attracted plenty of scrutiny from news reporters, animal-rights campaigners, and even fraud investigators at the Securities and Exchange Commission. Many of the questions surround its treatment of test animals and whether it rushed to try the implant in people.

More recently, Musk has started using his X platform to badger and bully heads of state and was named by Donald Trump to co-lead a so-called Department of Government Efficiency, which Musk says will “get rid of nonsensical regulations” and potentially gut some DC agencies. 

During 2025, watch for whether Musk uses his digital bullhorn to give health regulators pointed feedback on how they’re handling Neuralink.

Other efforts

Don’t forget that Neuralink isn’t the only company working on brain implants. A company called Synchron has one that’s inserted into the brain through a blood vessel, which it’s also testing in human trials of brain control over computers. Other companies, including Paradromics, Precision Neuroscience, and BlackRock Neurotech, are also developing advanced brain-computer interfaces.

Special thanks to Ryan Tanaka of Neura Pod for pointing us to Neuralink’s public announcements and projections.

Deciding the fate of “leftover” embryos

This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.

Over the past few months, I’ve been working on a piece about IVF embryos. The goal of in vitro fertilization is to create babies via a bit of lab work: Trigger the release of lots of eggs, introduce them to sperm in a lab, transfer one of the resulting embryos into a person’s uterus, and cross your fingers for a healthy pregnancy. Sometimes it doesn’t work. But often it does. For the article, I explored what happens to the healthy embryos that are left over.

I spoke to Lisa Holligan, who had IVF in the UK around five years ago. Holligan donated her “genetically abnormal” embryos for scientific research. But she still has one healthy embryo frozen in storage. And she doesn’t know what to do with it.

She’s not the only one struggling with the decision. “Leftover” embryos are kept frozen in storage tanks, where they sit in little straws, invisible to the naked eye, their growth paused in a state of suspended animation. What happens next is down to personal choice—but that choice can be limited by a complex web of laws and ethical and social factors.

These days, responsible IVF clinics will always talk to people about the possibility of having leftover embryos before they begin treatment. Intended parents will sign a form indicating what they would like to happen to those embryos. Typically, that means deciding early on whether they might like any embryos they don’t end up using to be destroyed or donated, either to someone else trying to conceive or for research.

But it can be really difficult to make these decisions before you’ve even started treatment. People seeking fertility treatment will usually have spent a long time trying to get pregnant. They are hoping for healthy embryos, and some can’t imagine having any left over—or how they might feel about them.

For a lot of people, embryos are not just balls of cells. They hold the potential for life, after all. Some people see them as children, waiting to be born. Some even name their embryos, or call them their “freezer babies.” Others see them as the product of a long, exhausting, and expensive IVF journey.

Holligan says that she initially considered donating her embryo to another person, but her husband disagreed. He saw the embryo as their child and said he wouldn’t feel comfortable with giving it up to another family. “I started having these thoughts about a child coming to me when they’re older, saying they’ve had a terrible life, and [asking] ‘Why didn’t you have me?’” she told me.

Holligan lives in the UK, where you can store your embryos for up to 55 years. Destroying or donating them are also options. That’s not the case in other countries. In Italy, for example, embryos cannot be destroyed or donated. Any that are frozen will remain that way forever, unless the law changes at some point.

In the US, regulations vary by state. The patchwork of laws means that one state can bestow a legal status on embryos, giving them the same rights as children, while another might have no legislation in place at all.

No one knows for sure how many embryos are frozen in storage tanks, but the figure is thought to be somewhere between 1 million and 10 million in the US alone. Some of these embryos have been in storage for years or decades. In some cases, the intended parents have deliberately chosen this, opting to pay hundreds of dollars per year in fees.

But in other cases, clinics have lost touch with their clients. Many of these former clients have stopped paying for the storage of their embryos, but without up-to-date consent forms, clinics can be reluctant to destroy them. What if the person comes back and wants to use those embryos after all?

“Most clinics, if they have any hesitation or doubt or question, will err on the side of holding on to those embryos and not discarding them,” says Sigal Klipstein, a reproductive endocrinologist at InVia Fertility Center in Chicago, who also chairs the ethics committee of the American Society for Reproductive Medicine. “Because it’s kind of like a one-way ticket.”

Klipstein thinks one of the reasons why some embryos end up “abandoned” in storage is that the people who created them can’t bring themselves to destroy them. “It’s just very emotionally difficult for someone who has wanted so much to have a family,” she tells me.

Klipstein says she regularly talks to her patients about what to do with leftover embryos. Even people who make the decision with confidence can change their minds, she says. “We’ve all had those patients who have discarded embryos and then come back six months or a year later and said: ‘Oh, I wish I had those embryos,’” she tells me. “Those [embryos may have been] their best chance of pregnancy.”

Those who do want to discard their embryos have options. Often, the embryos will simply be exposed to air and then disposed of. But some clinics will also offer to transfer them at a time or place where a pregnancy is extremely unlikely to result. This “compassionate transfer,” as it is known, might be viewed as a more “natural” way to dispose of the embryo.

But it’s not for everyone. Holligan has experienced multiple miscarriages and wonders if a compassionate transfer might feel similar. She wonders if it might just end up “putting [her] body and mind through unnecessary stress.”

Ultimately, for Holligan and many others in a similar position, the choice remains a difficult one. “These are … very desired embryos,” says Klipstein. “The purpose of going through IVF was to create embryos to make babies. And [when people] have these embryos, and they’ve completed their family plan, they’re in a place they couldn’t have imagined.”


Now read the rest of The Checkup

Read more from MIT Technology Review‘s archive

Our relationship with embryos is unique, and a bit all over the place. That’s partly because we can’t agree on their moral status. Are they more akin to people or property, or something in between? Who should get to decide their fate? While we get to the bottom of these sticky questions, millions of embryos are stuck in suspended animation—some of them indefinitely.

It is estimated that over 12 million babies have been born through IVF. The development of the Nobel Prize–winning technology behind the procedure relied on embryo research. Some worry that donating embryos for research can be onerous—and that valuable embryos are being wasted as a result.

Fertility rates around the world are dropping below the levels needed to maintain stable populations. But IVF can’t save us from a looming fertility crisis. Gender equality and family-friendly policies are much more likely to prove helpful

Two years ago, the US Supreme Court overturned Roe v. Wade, a legal decision that protected the right to abortion. Since then, abortion bans have been enacted in multiple states. But in November of last year, some states voted to extend and protect access to abortion, and voters in Missouri supported overturning the state’s ban.

Last year, a ruling by the Alabama Supreme Court that embryos count as children ignited fears over access to fertility treatments in a state that had already banned abortion. The move could also have implications for the development of technologies like artificial uteruses and synthetic embryos, my colleague Antonio Regalado wrote at the time.

From around the web

It’s not just embryos that are frozen as part of fertility treatments. Eggs, sperm, and even ovarian and testicular tissue can be stored too. A man who had immature testicular tissue removed and frozen before undergoing chemotherapy as a child 16 years ago had the tissue reimplanted in a world first, according to the team at University Hospital Brussels that performed the procedure around a month ago. The tissue was placed into the man’s testicle and scrotum, and scientists will wait a year before testing to see if he is successfully producing sperm. (UZ Brussel)

The Danish pharmaceutical company Novo Nordisk makes half the world’s insulin. Now it is better known as the manufacturer of the semaglutide drug Ozempic. How will the sudden shift affect the production and distribution of these medicines around the world? (Wired)

The US has not done enough to prevent the spread of the H5N1 virus in dairy cattle. The response to bird flu is a national embarrassment, argues Katherine J. Wu. (The Atlantic)

Elon Musk has said that if all goes well, millions of people will have brain-computer devices created by his company Neuralink implanted within 10 years. In reality, progress is slower—so far, Musk has said that three people have received the devices. My colleague Antonio Regalado predicts what we can expect from Neuralink in 2025. (MIT Technology Review)

OpenAI has created an AI model for longevity science

When you think of AI’s contributions to science, you probably think of AlphaFold, the Google DeepMind protein-folding program that earned its creator a Nobel Prize last year.

Now OpenAI says it’s getting into the science game too—with a model for engineering proteins.

The company says it has developed a language model that dreams up proteins capable of turning regular cells into stem cells—and that it has handily beat humans at the task.

The work represents OpenAI’s first model focused on biological data and its first public claim that its models can deliver unexpected scientific results. As such, it is a step toward determining whether or not AI can make true discoveries, which some argue is a major test on the pathway to “artificial general intelligence.”

Last week, OpenAI CEO Sam Altman said he was “confident” his company knows how to build an AGI, adding that “superintelligent tools could massively accelerate scientific discovery and innovation well beyond what we are capable of doing on our own.” 

The protein engineering project started a year ago when Retro Biosciences, a longevity research company based in San Francisco, approached OpenAI about working together.

That link-up did not happen by chance. Sam Altman, the CEO of OpenAI, personally funded Retro with $180 million, as MIT Technology Review first reported in 2023.

Retro has the goal of extending the normal human lifespan by 10 years. For that, it studies what are called Yamanaka factors. Those are a set of proteins that, when added to a human skin cell, will cause it to morph into a young-seeming stem cell, a type that can produce any other tissue in the body. 

It’s a phenomenon that researchers at Retro, and at richly funded companies like Altos Labs, see as the possible starting point for rejuvenating animals, building human organs, or providing supplies of replacement cells.

But such cell “reprogramming” is not very efficient. It takes several weeks, and less than 1% of cells treated in a lab dish will complete the rejuvenation journey.

OpenAI’s new model, called GPT-4b micro, was trained to suggest ways to re-engineer the protein factors to increase their function. According to OpenAI, researchers used the model’s suggestions to change two of the Yamanaka factors to be more than 50 times as effective—at least according to some preliminary measures. 

“Just across the board, the proteins seem better than what the scientists were able to produce by themselves,” says John Hallman, an OpenAI researcher.

Hallman and OpenAI’s Aaron Jaech, as well as Rico Meinl from Retro, were the model’s lead developers.

Outside scientists won’t be able to tell if the results are real until they’re published, something the companies say they are planning. Nor is the model available for wider use—it’s still a bespoke demonstration, not an official product launch.

“This project is meant to show that we’re serious about contributing to science,” says Jaech. “But whether those capabilities will come out to the world as a separate model or whether they’ll be rolled into our mainline reasoning models—that’s still to be determined.”

The model does not work the same way as Google’s AlphaFold, which predicts what shape proteins will take. Since the Yamanaka factors are unusually floppy and unstructured proteins, OpenAI said, they called for a different approach, which its large language models were suited to.

The model was trained on examples of protein sequences from many species, as well as information on which proteins tend to interact with one another. While that’s a lot of data, it’s just a fraction of what OpenAI’s flagship chatbots were trained on, making GPT-4b an example of a “small language model” that works with a focused data set.

Once Retro scientists were given the model, they tried to steer it to suggest possible redesigns of the Yamanaka proteins. The prompting tactic used is similar to the “few-shot” method, in which a user queries a chatbot by providing a series of examples with answers, followed by an example for the bot to respond to.

Although genetic engineers have ways to direct evolution of molecules in the lab, they can usually test only so many possibilities. And even a protein of typical length can be changed in nearly infinite ways (since they’re built from hundreds of amino acids, and each acid comes in 20 possible varieties).

OpenAI’s model, however, often spits out suggestions in which a third of the amino acids in the proteins were changed.

an image of Fibroblasts on Day 1; an image of Cells reprogrammed with SOX@, KLF4, OCT4, and MYC on Day 10; and an image of cells reprogrammed with RetroSOX, RetroKLF, OCT4, and MYC on Day 10

OPENAI

“We threw this model into the lab immediately and we got real-world results,” says Retro’s CEO, Joe Betts-Lacroix. He says the model’s ideas were unusually good, leading to improvements over the original Yamanaka factors in a substantial fraction of cases.

Vadim Gladyshev, a Harvard University aging researcher who consults with Retro, says better ways of making stem cells are needed. “For us, it would be extremely useful. [Skin cells] are easy to reprogram, but other cells are not,” he says. “And to do it in a new species—it’s often extremely different, and you don’t get anything.” 

How exactly the GPT-4b arrives at its guesses is still not clear—as is often the case with AI models. “It’s like when AlphaGo crushed the best human at Go, but it took a long time to find out why,” says Betts-Lacroix. “We are still figuring out what it does, and we think the way we apply this is only scratching the surface.”

OpenAI says no money changed hands in the collaboration. But because the work could benefit Retro—whose biggest investor is Altman—the announcement may add to questions swirling around the OpenAI CEO’s side projects.

Last year, the Wall Street Journal said Altman’s wide-ranging investments in private tech startups amount to an “opaque investment empire” that is “creating a mounting list of potential conflicts,” since some of these companies also do business with OpenAI.

In Retro’s case, simply being associated with Altman, OpenAI, and the race toward AGI could boost its profile and increase its ability to hire staff and raise funds. Betts-Lacroix did not answer questions about whether the early-stage company is currently in fundraising mode. 

OpenAI says Altman was not directly involved in the work and that it never makes decisions based on Altman’s other investments. 

Inside the strange limbo facing millions of IVF embryos

Lisa Holligan already had two children when she decided to try for another baby. Her first two pregnancies had come easily. But for some unknown reason, the third didn’t. Holligan and her husband experienced miscarriage after miscarriage after miscarriage.

Like many other people struggling to conceive, Holligan turned to in vitro fertilization, or IVF. The technology allows embryologists to take sperm and eggs and fuse them outside the body, creating embryos that can then be transferred into a person’s uterus.

The fertility clinic treating Holligan was able to create six embryos using her eggs and her husband’s sperm. Genetic tests revealed that only three of these were “genetically normal.” After the first was transferred, Holligan got pregnant. Then she experienced yet another miscarriage. “I felt numb,” she recalls. But the second transfer, which took place several months later, stuck. And little Quinn, who turns four in February, was the eventual happy result. “She is the light in our lives,” says Holligan.

Holligan, who lives in the UK, opted to donate her “genetically abnormal” embryos for scientific research. But she still has one healthy embryo frozen in storage. And she doesn’t know what to do with it.

Should she and her husband donate it to another family? Destroy it? “It’s almost four years down the line, and we still haven’t done anything with [the embryo],” she says. The clinic hasn’t been helpful—Holligan doesn’t remember talking about what to do with leftover embryos at the time, and no one there has been in touch with her for years, she says.

Holligan’s embryo is far from the only one in this peculiar limbo. Millions—or potentially tens of millions—of embryos created through IVF sit frozen in time, stored in cryopreservation tanks around the world. The number is only growing thanks to advances in technology, the rising popularity of IVF, and improvements in its success rates. 

At a basic level, an embryo is simply a tiny ball of a hundred or so cells. But unlike other types of body tissue, it holds the potential for life. Many argue that this endows embryos with a special moral status, one that requires special protections. The problem is that no one can really agree on what that status is. To some, they’re human cells and nothing else. To others, they’re morally equivalent to children. Many feel they exist somewhere between those two extremes.

There are debates, too, over how we should classify embryos in law. Are they property? Do they have a legal status? These questions are important: There have been multiple legal disputes over who gets to use embryos, who is responsible if they are damaged, and who gets the final say over their fate. And the answers will depend not only on scientific factors, but also on ethical, cultural, and religious ones.  

The options currently available to people with leftover IVF embryos mirror this confusion. As a UK resident, Holligan can choose to discard her embryos, make them available to other prospective parents, or donate them for research. People in the US can also opt for “adoption,” “placing” their embryos with families they get to choose. In Germany, people are not typically allowed to freeze embryos at all. And in Italy, embryos that are not used by the intended parents cannot be discarded or donated. They must remain frozen, ostensibly forever. 

While these embryos persist in suspended animation, patients, clinicians, embryologists, and legislators must grapple with the essential question of what we should do with them. What do these embryos mean to us? Who should be responsible for them? 

Meanwhile, many of these same people are trying to find ways to bring down the total number of embryos in storage. Maintenance costs are high. Some clinics are running out of space. And with a greater number of embryos in storage, there are more opportunities for human error. They are grappling with how to get a handle on the growing number of embryos stuck in storage with nowhere to go.

The embryo boom

There are a few reasons why this has become such a conundrum. And they largely come down to an increasing demand for IVF and improvements in the way it is practiced. “It’s a problem of our own creation,” says Pietro Bortoletto, a reproductive endocrinologist at Boston IVF in Massachusetts. IVF has only become as successful as it is today by “generating lots of excess eggs and embryos along the way,” he says. 

To have the best chance of creating healthy embryos that will attach to the uterus and grow in a successful pregnancy, clinics will try to collect multiple eggs. People who undergo IVF will typically take a course of hormone injections to stimulate their ovaries. Instead of releasing a single egg that month, they can expect to produce somewhere between seven and 20 eggs. These eggs can be collected via a needle that passes through the vagina and into the ovaries. The eggs are then taken to a lab, where they are introduced to sperm. Around 70% to 80% of IVF eggs are successfully fertilized to create embryos.

The embryos are then grown in the lab. After around five to seven days an embryo reaches a stage of development at which it is called a blastocyst, and it is ready to be transferred to a uterus. Not all IVF embryos reach this stage, however—only around 30% to 50% of them make it to day five. This process might leave a person with no viable embryos. It could also result in more than 10, only one of which is typically transferred in each pregnancy attempt. In a typical IVF cycle, one embryo might be transferred to the person’s uterus “fresh,” while any others that were created are frozen and stored.

IVF success rates have increased over time, in large part thanks to improvements in this storage technology. A little over a decade ago, embryologists tended to use a “slow freeze” technique, says Bortoletto, and many embryos didn’t survive the process. Embryos are now vitrified instead, using liquid nitrogen to rapidly cool them from room temperature to -196 °C in less than two seconds. Vitrification essentially turns all the water in the embryos into a glasslike state, avoiding the formation of damaging ice crystals. 

Now, clinics increasingly take a “freeze all” approach, in which they cryopreserve all the viable embryos and don’t start transferring them until later. In some cases, this is so that the clinic has a chance to perform genetic tests on the embryo they plan to transfer.

An assortment of sperm and embryos, preserved in liquid nitrogen.
ALAMY

Once a lab-grown embryo is around seven days old, embryologists can remove a few cells for preimplantation genetic testing (PGT), which screens for genetic factors that might make healthy development less likely or predispose any resulting children to genetic diseases. PGT is increasingly popular in the US—in 2014, it was used in 13% of IVF cycles, but by 2016, that figure had increased to 27%. Embryos that undergo PGT have to be frozen while the tests are run, which typically takes a week or two, says Bortoletto: “You can’t continue to grow them until you get those results back.”

And there doesn’t seem to be a limit to how long an embryo can stay in storage. In 2022, a couple in Oregon had twins who developed from embryos that had been frozen for 30 years.

Put this all together, and it’s easy to see how the number of embryos in storage is rocketing. We’re making and storing more embryos than ever before. When you combine that with the growing demand for IVF, which is increasing in use by the year, perhaps it’s not surprising that the number of embryos sitting in storage tanks is estimated to be in the millions.

I say estimated, because no one really knows how many there are. In 2003, the results of a survey of fertility clinics in the US suggested that there were around 400,000 in storage. Ten years later, in 2013, another pair of researchers estimated that, in total, around 1.4 million embryos had been cryopreserved in the US. But Alana Cattapan, now a political scientist at the University of Waterloo in Ontario, Canada, and her colleagues found flaws in the study and wrote in 2015 that the number could be closer to 4 million.  

That was a decade ago. When I asked embryologists what they thought the number might be in the US today, I got responses between 1 million and 10 million. Bortoletto puts it somewhere around 5 million.

Globally, the figure is much higher. There could be tens of millions of embryos, invisible to the naked eye, kept in a form of suspended animation. Some for months, years, or decades. Others indefinitely.

Stuck in limbo

In theory, people who have embryos left over from IVF have a few options for what to do with them. They could donate the embryos for someone else to use. Often this can be done anonymously (although genetic tests might later reveal the biological parents of any children that result). They could also donate the embryos for research purposes. Or they could choose to discard them. One way to do this is to expose the embryos to air, causing the cells to die.

Studies suggest that around 40% of people with cryopreserved embryos struggle to make this decision, and that many put it off for five years or more. For some people, none of the options are appealing.

In practice, too, the available options vary greatly depending on where you are. And many of them lead to limbo.

Take Spain, for example, which is a European fertility hub, partly because IVF there is a lot cheaper than in other Western European countries, says Giuliana Baccino, managing director of New Life Bank, a storage facility for eggs and sperm in Buenos Aires, Argentina, and vice chair of the European Fertility Society. Operating costs are low, and there’s healthy competition—there are around 330 IVF clinics operating in Spain. (For comparison, there are around 500 IVF clinics in the US, which has a population almost seven times greater.)

Baccino, who is based in Madrid, says she often hears of foreign patients in their late 40s who create eight or nine embryos for IVF in Spain but end up using only one or two of them. They go back to their home countries to have their babies, and the embryos stay in Spain, she says. These individuals often don’t come back for their remaining embryos, either because they have completed their families or because they age out of IVF eligibility (Spanish clinics tend not to offer the treatment to people over 50). 

Doctors hands removing embryo samples from cryogenic storage
An embryo sample is removed from cryogenic storage.
GETTY IMAGES

In 2023, the Spanish Fertility Society estimated that there were 668,082 embryos in storage in Spain, and that around 60,000 of them were “in a situation of abandonment.” In these cases the clinics might not be able to reach the intended parents, or might not have a clear directive from them, and might not want to destroy any embryos in case the patients ask for them later. But Spanish clinics are wary of discarding embryos even when they have permission to do so, says Baccino. “We always try to avoid trouble,” she says. “And we end up with embryos in this black hole.”

This happens to embryos in the US, too. Clinics can lose touch with their patients, who may move away or forget about their remaining embryos once they have completed their families. Other people may put off making decisions about those embryos and stop communicating with the clinic. In cases like these, clinics tend to hold onto the embryos, covering the storage fees themselves.

Nowadays clinics ask their patients to sign contracts that cover long-term storage of embryos—and the conditions of their disposal. But even with those in hand, it can be easier for clinics to leave the embryos in place indefinitely. “Clinics are wary of disposing of them without explicit consent, because of potential liability,” says Cattapan, who has researched the issue. “People put so much time, energy, money into creating these embryos. What if they come back?”

Bortoletto’s clinic has been in business for 35 years, and the handful of sites it operates in the US have a total of over 47,000 embryos in storage, he says. “Our oldest embryo in storage was frozen in 1989,” he adds. 

Some people may not even know where their embryos are. Sam Everingham, who founded and directs Growing Families, an organization offering advice on surrogacy and cross-border donations, traveled with his partner from their home in Melbourne, Australia, to India to find an egg donor and surrogate back in 2009. “It was a Wild West back then,” he recalls. Everingham and his partner used donor eggs to create eight embryos with their sperm.

Everingham found the experience of trying to bring those embryos to birth traumatic. Baby Zac was stillborn. Baby Ben died at seven weeks. “We picked ourselves up and went again,” he recalls. Two embryo transfers were successful, and the pair have two daughters today.

But the fate of the rest of their embryos is unclear. India’s government decided to ban commercial surrogacy for foreigners in 2015, and Everingham lost track of where they are. He says he’s okay with that. As far as he’s concerned, those embryos are just cells.

He knows not everyone feels the same way. A few days before we spoke, Everingham had hosted a couple for dinner. They had embryos in storage and couldn’t agree on what to do with them. “The mother … wanted them donated to somebody,” says Everingham. Her husband was very uncomfortable with the idea. “[They have] paid storage fees for 14 years for those embryos because neither can agree on what to do with them,” says Everingham. “And this is a very typical scenario.”

Lisa Holligan’s experience is similar. Holligan thought she’d like to donate her last embryo to another person—someone else who might have been struggling to conceive. “But my husband and I had very different views on it,” she recalls. He saw the embryo as their child and said he wouldn’t feel comfortable with giving it up to another family. “I started having these thoughts about a child coming to me when they’re older, saying they’ve had a terrible life, and [asking] ‘Why didn’t you have me?’” she says.

After all, her daughter Quinn began as an embryo that was in storage for months. “She was frozen in time. She could have been frozen for five years like [the leftover] embryo and still be her,” she says. “I know it sounds a bit strange, but this embryo could be a child in 20 years’ time. The science is just mind-blowing, and I think I just block it out. It’s far too much to think about.”

No choice at all

Choosing the fate of your embryos can be difficult. But some people have no options at all.

This is the case in Italy, where the laws surrounding assisted reproductive technology have grown increasingly restrictive. Since 2004, IVF has been accessible only to heterosexual couples who are either married or cohabiting. Surrogacy has also been prohibited in the country for the last 20 years, and in 2024, it was made a “universal crime.” The move means Italians can be prosecuted for engaging in surrogacy anywhere in the world, a position Italy has also taken on the crimes of genocide and torture, says Sara Dalla Costa, a lawyer specializing in assisted reproduction and an IVF clinic manager at Instituto Bernabeu on the outskirts of Venice.

The law surrounding leftover embryos is similarly inflexible. Dalla Costa says there are around 900,000 embryos in storage in Italy, basing the estimate on figures published in 2021 and the number of IVF cycles performed since then. By law, these embryos cannot be discarded. They cannot be donated to other people, and they cannot be used for research. 

Even when genetic tests show that the embryo has genetic features making it “incompatible with life,” it must remain in storage, forever, says Dalla Costa. 

“There are a lot of patients that want to destroy embryos,” she says. For that, they must transfer their embryos to Spain or other countries where it is allowed.

Even people who want to use their embryos may “age out” of using them. Dalla Costa gives the example of a 48-year-old woman who undergoes IVF and creates five embryos. If the first embryo transfer happens to result in a successful pregnancy, the other four will end up in storage. Once she turns 50, this woman won’t be eligible for IVF in Italy. Her remaining embryos become stuck in limbo. “They will be stored in our biobanks forever,” says Dalla Costa.

Dalla Costa says she has “a lot of examples” of couples who separate after creating embryos together. For many of them, the stored embryos become a psychological burden. With no way of discarding them, these couples are forever connected through their cryopreserved cells. “A lot of our patients are stressed for this reason,” she says.

Earlier this year, one of Dalla Costa’s clients passed away, leaving behind the embryos she’d created with her husband. He asked the clinic to destroy them. In cases like these, Dalla Costa will contact the Italian Ministry of Health. She has never been granted permission to discard an embryo, but she hopes that highlighting cases like these might at least raise awareness about the dilemmas the country’s policies are creating for some people.

Snowflakes and embabies

In Italy, embryos have a legal status. They have protected rights and are viewed almost as children. This sentiment isn’t specific to Italy. It is shared by plenty of individuals who have been through IVF. “Some people call them ‘embabies’ or ‘freezer babies,’” says Cattapan.

It is also shared by embryo adoption agencies in the US. Beth Button is executive director of one such program, called Snowflakes—a division of Nightlight Christian Adoptions agency, which considers cryopreserved embryos to be children, frozen in time, waiting to be born. Snowflakes matches embryo donors, or “placing families,” with recipients, termed “adopting families.” Both parties share their information and essentially get to choose who they donate to or receive from. By the end of 2024, 1,316 babies had been born through the Snowflakes embryo adoption program, says Button. 

Button thinks that far too many embryos are being created in IVF labs around the US. Around 10 years ago, her agency received a donation from a couple that had around 38 leftover embryos to donate. “We really encourage [people with leftover embryos in storage] to make a decision [about their fate], even though it’s an emotional, difficult decision,” she says. “Obviously, we just try to keep [that discussion] focused on the child,” she says. “Is it better for these children to be sitting in a freezer, even though that might be easier for you, or is it better for them to have a chance to be born into a loving family? That kind of pushes them to the point where they’re ready to make that decision.”

Button and her colleagues feel especially strongly about embryos that have been in storage for a long time. These embryos are usually difficult to place, because they are thought to be of poorer quality, or less likely to successfully thaw and result in a healthy birth. The agency runs a program called Open Hearts specifically to place them, along with others that are harder to match for various reasons. People who accept one but fail to conceive are given a shot with another embryo, free of charge.

These nitrogen tanks at New Hope Fertility Center in New York hold tens of thousands of frozen embryos and eggs.
GETTY IMAGES

“We have seen perfectly healthy children born from very old embryos, [as well as] embryos that were considered such poor quality that doctors didn’t even want to transfer them,” says Button. “Right now, we have a couple who is pregnant with [an embryo] that was frozen for 30 and a half years. If that pregnancy is successful, that will be a record for us, and I think it will be a worldwide record as well.”

Many embryologists bristle at the idea of calling an embryo a child, though. “Embryos are property. They are not unborn children,” says Bortoletto. In the best case, embryos create pregnancies around 65% of the time, he says. “They are not unborn children,” he repeats.

Person or property?

In 2020, an unauthorized person allegedly entered an IVF clinic in Alabama and pulled frozen embryos from storage, destroying them. Three sets of intended parents filed suit over their “wrongful death.” A trial court dismissed the claims, but the Alabama Supreme Court disagreed, essentially determining that those embryos were people. The ruling shocked many and was expected to have a chilling effect on IVF in the state, although within a few weeks, the state legislature granted criminal and civil immunity to IVF clinics.

But the Alabama decision is the exception. While there are active efforts in some states to endow embryos with the same legal rights as people, a move that could potentially limit access to abortion, “most of the [legal] rulings in this area have made it very clear that embryos are not people,” says Rich Vaughn, an attorney specializing in fertility law and the founder of the US-based International Fertility Law Group. At the same time, embryos are not just property. “They’re something in between,” says Vaughn. “They’re sort of a special type of property.” 

UK law takes a similar approach: The language surrounding embryos and IVF was drafted with the idea that the embryo has some kind of “special status,” although it was never made entirely clear exactly what that special status is, says James Lawford Davies, a solicitor and partner at LDMH Partners, a law firm based in York, England, that specializes in life sciences. Over the years, the language has been tweaked to encompass embryos that might arise from IVF, cloning, or other means; it is “a bit of a fudge,” says Lawford Davies. Today, the official—if somewhat circular—legal definition in the Human Fertilisation and Embryology Act reads: “embryo means a live human embryo.” 

And while people who use their eggs or sperm to create embryos might view these embryos as theirs, according to UK law, embryos are more like “a stateless bundle of cells,” says Lawford Davies. They’re not quite property—people don’t own embryos. They just have control over how they are used. 

Many legal disputes revolve around who has control. This was the experience of Natallie Evans, who created embryos with her then partner Howard Johnston in the UK in 2001. The couple separated in 2002. Johnston wrote to the clinic to ask that their embryos be destroyed. But Evans, who had been diagnosed with ovarian cancer in 2001, wanted to use them. She argued that Johnston had already consented to their creation, storage, and use and should not be allowed to change his mind. The case eventually made it to the European Court of Human Rights, and Evans lost. The case set a precedent that consent was key and could be withdrawn at any time.

In Italy, on the other hand, withdrawing consent isn’t always possible. In 2021, a case like Natallie Evans’s unfolded in the Italian courts: A woman who wanted to proceed with implantation after separating from her partner went to court for authorization. “She said that it was her last chance to be a mother,” says Dalla Costa. The judge ruled in her favor.

Dalla Costa’s clinics in Italy are now changing their policies to align with this decision. Male partners must sign a form acknowledging that they cannot prevent embryos from being used once they’ve been created.

The US situation is even more complicated, because each state has its own approach to fertility regulation. When I looked through a series of published legal disputes over embryos, I found little consistency—sometimes courts ruled to allow a woman to use an embryo without the consent of her former partner, and sometimes they didn’t. “Some states have comprehensive … legislation; some do not,” says Vaughn. “Some have piecemeal legislation, some have only case law, some have all of the above, some have none of the above.”

The meaning of an embryo

So how should we define an embryo? “It’s the million-dollar question,” says Heidi Mertes, a bioethicist at Ghent University in Belgium. Some bioethicists and legal scholars, including Vaughn, think we’d all stand to benefit from clear legal definitions. 

Risa Cromer, a cultural anthropologist at Purdue University in Indiana, who has spent years researching the field, is less convinced. Embryos exist in a murky, in-between state, she argues. You can (usually) discard them, or transfer them, but you can’t sell them. You can make claims against damages to them, but an embryo is never viewed in the same way as a car, for example. “It doesn’t fit really neatly into that property category,” says Cromer. “But, very clearly, it doesn’t fit neatly into the personhood category either.”

And there are benefits to keeping the definition vague, she adds: “There is, I think, a human need for there to be a wide range of interpretive space for what IVF embryos are or could be.”

That’s because we don’t have a fixed moral definition of what an embryo is. Embryos hold special value even for people who don’t view them as children. They hold potential as human life. They can come to represent a fertility journey—one that might have been expensive, exhausting, and traumatizing.  “Even for people who feel like they’re just cells, it still cost a lot of time, money, [and effort] to get those [cells],” says Cattapan.

“I think it’s an illusion that we might all agree on what the moral status of an embryo is,” Mertes says.

In the meantime, a growing number of embryologists, ethicists, and researchers are working to persuade fertility clinics and their patients not to create or freeze so many embryos in the first place. Early signs aren’t promising, says Baccino. The patients she has encountered aren’t particularly receptive to the idea. “They think, ‘If I will pay this amount for a cycle, I want to optimize my chances, so in my case, no,’” she says. She expects the number of embryos in storage to continue to grow.

Holligan’s embryo has been in storage for almost five years. And she still doesn’t know what to do with it. She tears up as she talks through her options. Would discarding the embryo feel like a miscarriage? Would it be a sad thing? If she donated the embryo, would she spend the rest of her life wondering what had become of her biological child, and whether it was having a good life? Should she hold on to the embryo for another decade in case her own daughter needs to use it at some point?

“The question [of what to do with the embryo] does pop into my head, but I quickly try to move past it and just say ‘Oh, that’s something I’ll deal with at a later time,’” says Holligan. “I’m sure [my husband] does the same.”

The accumulation of frozen embryos is “going to continue this way for some time until we come up with something that fully addresses everyone’s concerns,” says Vaughn. But will we ever be able to do that?

“I’m an optimist, so I’m gonna say yes,” he says with a hopeful smile. “But I don’t know at the moment.”